No Data
No Data
Goldman Sachs: The Q1 performance of U.S. pharmaceutical stocks is reassuring, and the Industry sentiment is slightly becoming more positive.
Goldman Sachs stated that amid cautious sentiment from investors towards the USA pharmaceutical sector before the Earnings Reports season, the performance of USA pharmaceutical companies that have reported results so far for the first quarter has not been worse than expected, and in some cases, it has even exceeded expectations.
Earnings Preview: Accuray to Report Financial Results Post-market on April 30
Accuray to Report Third Quarter Fiscal 2025 Financial Results on April 30, 2025
Healthcare Stocks Aren't a Shelter From the Tariff Storm -- Barrons.com
Trump Defends Tariffs, Announces Pharmaceutical Levies Coming Soon
Pharma Stocks Have Risk of U.S. Tariffs Priced In -- Market Talk